Sheaff Brock Investment Advisors LLC lessened its stake in Intrexon Corporation (NYSE:XON) by 0.3% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 34,242 shares of the biotechnology company’s stock after selling 100 shares during the quarter. Sheaff Brock Investment Advisors LLC’s holdings in Intrexon Corporation were worth $825,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Federated Investors Inc. PA acquired a new stake in Intrexon Corporation in the 2nd quarter valued at about $172,000. Pacer Advisors Inc. boosted its stake in Intrexon Corporation by 21.6% during the 1st quarter. Pacer Advisors Inc. now owns 7,352 shares of the biotechnology company’s stock worth $146,000 after acquiring an additional 1,305 shares during the last quarter. SG Americas Securities LLC bought a new position in Intrexon Corporation during the 1st quarter worth approximately $164,000. Cullinan Associates Inc. bought a new position in Intrexon Corporation during the 2nd quarter worth approximately $201,000. Finally, Principal Financial Group Inc. bought a new position in Intrexon Corporation during the 2nd quarter worth approximately $212,000. Hedge funds and other institutional investors own 82.27% of the company’s stock.
In other news, COO Andrew J. Last bought 2,000 shares of the company’s stock in a transaction that occurred on Monday, August 14th. The stock was bought at an average price of $19.99 per share, for a total transaction of $39,980.00. Following the transaction, the chief operating officer now directly owns 2,000 shares of the company’s stock, valued at approximately $39,980. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Randal J. Kirk bought 132,625 shares of the company’s stock in a transaction that occurred on Friday, August 11th. The stock was purchased at an average price of $18.85 per share, with a total value of $2,499,981.25. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 144,569 shares of company stock worth $2,719,429. Company insiders own 55.10% of the company’s stock.
Several research firms recently weighed in on XON. BidaskClub lowered shares of Intrexon Corporation from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 22nd. Northland Securities set a $30.00 price target on shares of Intrexon Corporation and gave the company a “buy” rating in a research note on Monday, August 7th. Finally, Zacks Investment Research lowered shares of Intrexon Corporation from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $37.60.
Shares of Intrexon Corporation (NYSE XON) opened at 18.89 on Friday. Intrexon Corporation has a 12 month low of $17.03 and a 12 month high of $32.90. The company’s market cap is $2.28 billion. The stock has a 50 day moving average of $19.65 and a 200-day moving average of $21.44.
Intrexon Corporation (NYSE:XON) last issued its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.05. Intrexon Corporation had a negative return on equity of 19.08% and a negative net margin of 60.63%. The company had revenue of $54.40 million for the quarter, compared to analysts’ expectations of $57.17 million. During the same period last year, the business earned ($0.42) EPS. Intrexon Corporation’s quarterly revenue was up 3.6% compared to the same quarter last year. On average, analysts forecast that Intrexon Corporation will post ($0.87) EPS for the current year.
About Intrexon Corporation
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with our FREE daily email newsletter.